AG
XLRN

Advisor Group’s Acceleron Pharma XLRN Stock Holding History

Advisor Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$10K Sell
182
-21,284
-99% -$970K ﹤0.01% 4390
2019
Q3 		$848K Sell
21,466
-5,213
-20% -$226K 0.01% 1247
2019
Q2 		$1.1M Buy
26,679
+12,777
+92% +$529K 0.01% 1079
2019
Q1 		$647K Buy
13,902
+9,646
+227% +$424K 0.01% 1411
2018
Q4 		$186K Buy
4,256
+3,606
+555% +$180K ﹤0.01% 2143
2018
Q3 		$37K Sell
650
-21,198
-97% -$1.04M ﹤0.01% 3506
2018
Q2 		$1.06M Buy
21,848
+2,524
+13% +$92K 0.01% 829
2018
Q1 		$755K Buy
19,324
+19,231
+20,678% +$817K 0.01% 1040
2017
Q4 		$3K Sell
93
-1,616
-95% -$60.6K ﹤0.01% 4616
2017
Q3 		$65K Sell
1,709
-6,610
-79% -$229K ﹤0.01% 2746
2017
Q2 		$253K Sell
8,319
-35
-0.4% -$1.01K ﹤0.01% 1609
2017
Q1 		$221K Buy
8,354
+4,551
+120% +$120K ﹤0.01% 1585
2016
Q4 		$97K Buy
3,803
+2,101
+123% +$66.6K ﹤0.01% 2091
2016
Q3 		$61K Buy
1,702
+1,576
+1,251% +$52.2K ﹤0.01% 2371
2016
Q2 		$3K Buy
+126
New +$4.1K ﹤0.01% 4018

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Advisor Group's XLRN Position: Q4 2019 in Review

Advisor Group reduced its Acceleron Pharma (XLRN) stake by 99% in Q4 2019, selling an estimated $970K and leaving 182 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #4390.

Advisor Group first reported a position in XLRN in Q2 2016 and has held it in 15 quarters since. The position peaked at $1.1M in Q2 2019. 183 funds tracked by Wall St. Rank hold XLRN as of Q4 2019.

  • Advisor Group held 182 shares of Acceleron Pharma worth $10K as of Q4 2019.
  • Advisor Group sold 21,284 Acceleron Pharma shares in Q4 2019, an estimated $970K.
  • Acceleron Pharma made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4390 holding.
  • Advisor Group first reported a position in Acceleron Pharma in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Acceleron Pharma position peaked at $1.1M in Q2 2019.
  • 183 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.